Why your hayfever might follow your cycle

The pattern you might have noticed — but never had explained

You track your hayfever. You know roughly which weeks are brutal and which are manageable. But if you're a woman who menstruates, you may have noticed something that doesn't line up neatly with the pollen forecast: some days are significantly worse than the count alone would predict. A clear morning in June that should be tolerable — and yet you're reaching for tissues before you've finished your coffee.

You're not imagining it. The biology is real, even if the research hasn't yet caught up with the full picture.

This article covers what science currently understands about the relationship between sex hormones and allergic rhinitis — from the molecular mechanics of oestrogen acting on mast cells, through what happens across the menstrual cycle, to the implications of contraception, pregnancy, and menopause. It's a story where the evidence is genuinely interesting but genuinely incomplete, and being honest about both matters.

---

The science: how oestrogen turns up the allergic volume

A switch that flips at puberty

Start with the population-level picture. In childhood, boys are more likely than girls to have allergic rhinitis — a male-to-female ratio of roughly 1.21 to 1. Then puberty arrives, and the ratio reverses. By adulthood, women predominate globally, though the difference is modest (Pinart et al., 2017). This crossover is too consistent to be coincidence. The leading explanation is hormonal: rising oestrogen promotes a Th2-skewed immune environment — the flavour of immunity associated with allergic responses — while testosterone appears to exert broadly immunosuppressive, protective effects.

So sex hormones aren't just background biology. They're active modulators of allergic reactivity.

What oestrogen does to the cells that trigger your symptoms

Mast cells are the sentinels of the allergic response — the cells that, when activated by allergen, release histamine and set off the sneezing, congestion, and itching cascade. It turns out they carry oestrogen receptors (specifically oestrogen receptor alpha, or ERα), and when oestradiol — the main circulating form of oestrogen — binds to them, the consequences are measurable.

Cocchiara et al. (1990) demonstrated that oestradiol enhances histamine release from both rat peritoneal mast cells and human basophils in a dose-dependent fashion, with sensitised human basophils releasing up to 41% more histamine in the presence of physiological oestradiol concentrations. Narita et al. (2006) showed that environmental oestrogens — chemicals that mimic oestradiol's receptor-binding activity — also trigger mast cell degranulation and amplify IgE-mediated allergic mediator release, suggesting this is a receptor-mediated class effect rather than a quirk of one molecule.

The mechanism is notably rapid. Rather than acting through the classical route of nuclear gene transcription, oestradiol triggers mast cell degranulation via a fast, non-genomic signalling pathway involving extracellular calcium influx. Blocking ERα with tamoxifen, or chelating calcium, abolishes the effect. Over longer timeframes, oestradiol also upregulates mast cell tryptase expression, increasing the total inflammatory payload available per degranulation event. Progesterone, rather than counteracting this, appears to act synergistically — further enhancing degranulation potential in some experimental models.

In nasal tissue specifically, oestrogen receptors are expressed on vascular endothelium, epithelial cells, submucosal glands, and immune cells. Oestradiol promotes mucosal vasodilation, increases vascular permeability, upregulates histamine H1 receptor expression, and supports eosinophil adhesion — a cocktail that, in the context of allergen exposure, could meaningfully amplify the pollen-triggered symptoms you're already experiencing.

Across the menstrual cycle: what the data suggest (and don't prove)

Given this mechanistic picture, you'd expect symptoms to track with oestrogen across the menstrual cycle — peaking around ovulation when oestradiol surges, perhaps modulating through the luteal phase as progesterone rises. Several small studies point in this direction.

Stübner et al. (1999) found that skin prick test reactivity in women with seasonal allergic rhinitis varied with cycle phase, with mid-cycle peaks correlating positively with serum oestradiol. Rhinomanometry data — measuring nasal airflow resistance — show that nasal obstruction tends to be highest around ovulation. A large Nordic-Baltic population study (Macsali et al., 2013; n=3,926) documented cyclical variation in respiratory symptoms across the menstrual cycle. And a questionnaire study by Salih & Abdulateef (2025) found that atopic symptoms — including rhinitis — were most commonly reported as worsening in the perimenstrual phase.

Aissani & Zitouni (2024) reviewed hormonal fluctuation effects across the cycle and described a consistent pattern: oestrogen peaks at ovulation appear to worsen nasal symptoms, particularly congestion, while the luteal phase may bring partial relief via progesterone's partial stabilising effect on mast cells — though this remains poorly characterised for nasal tissue.

Here is where the honesty must come in. No study has yet systematically measured validated symptom scores — the kind of standardised daily diaries (TNSS, VAS) used in clinical trials — across all four menstrual phases in women with confirmed allergic rhinitis, while also controlling for what they were actually exposed to pollen-wise on any given day. Philpott et al. (2004) documented steroid sex hormone effects on nasal airway patency across the normal menstrual cycle, but used rhinomanometry rather than patient-reported symptom scores. The clinical magnitude of cycle-related variation, and how it compares to the 30–50% TNSS reductions typically achieved with intranasal corticosteroids, remains uncalculated. The effect is probably real. Its size, relative to other drivers of your symptoms, is genuinely unknown.

---

What this means for you

If you menstruate and have hayfever

Approximately 30–40% of women with allergic disease report symptom worsening that tracks cyclically — typically worst around ovulation or in the days before menstruation (Nowak-Węgrzyn et al., 2019). The biology supports this. Your mast cells are more reactive when oestradiol is high. Your nasal mucosa is more vascular and more permeable. The same pollen load that you'd handle on day 5 of your cycle may hit harder on day 13.

This doesn't mean you're more allergic. It means the threshold for triggering symptoms shifts with your hormonal milieu.

If you use hormonal contraception

The picture here is counterintuitive. A large cross-sectional analysis using the All of Us database (Dick et al., 2025) found that women using systemic hormonal contraceptives had approximately 32% higher odds of allergic rhinitis compared to non-users (adjusted OR 1.32, 95% CI 1.20–1.44), with both oestrogen-containing and progestin-only formulations showing similar associations. This is an association, not a proven causal relationship — but it's a consistent finding.

What may be happening: combined oral contraceptives suppress the mid-cycle oestradiol surge and flatten luteal progesterone, potentially reducing the worst peaks of cycle-driven symptom amplification. However, they substitute a constant low-dose exogenous hormone environment that still maintains Th2 immune skewing, and may intensify neurogenic symptoms like sneezing in some women. The Bonfils et al. study (1999) found OC users showed reduced cycle-related variation in nasal airflow after allergen challenge, with natural-cycle women showing roughly 1.5–2× greater obstruction amplitude between phases — but this was a small study (n=23) using provocation rather than everyday symptom diaries.

In short: hormonal contraception may smooth out your symptom peaks while raising your overall floor. Whether this represents a net benefit for hayfever depends on your individual pattern.

If you're pregnant

Pregnancy rhinitis — congestion driven by hormonal and vascular changes unrelated to allergy — affects roughly 20% of pregnancies. If you already have allergic rhinitis, these two conditions stack. Women with pre-existing rhinitis appear particularly prone to developing pregnancy rhinitis on top, creating an additive symptom burden. Your allergic rhinitis may improve, stay the same, or worsen during pregnancy — it splits roughly one-third, one-third, one-third — but the rising oestrogen of the second trimester creates a strongly pro-inflammatory mucosal environment that tends to amplify any underlying IgE-mediated response (Dumitru et al., 2025).

Around perimenopause and beyond

The perimenopausal transition — characterised by erratic, swinging oestrogen rather than steady decline — appears to be a period of heightened allergic reactivity for some women. Fluctuating oestradiol may destabilise mast cell behaviour in ways that sustained (even high) levels do not. Interestingly, Lee et al. (2019) found that longer lifetime endogenous oestrogen exposure was associated with higher allergic rhinitis prevalence in postmenopausal women, while postmenopausal status overall was associated with decreased AR odds compared to premenopausal status. New-onset sensitisation specifically attributable to menopause is possible but remains poorly studied.

---

The evidence landscape: what we know, what we don't

The mechanistic case is reasonably solid. Oestradiol acts on mast cells via ERα, enhances histamine release dose-dependently, increases nasal mucosal reactivity, and promotes Th2-biased immune responses. This is consistent across multiple study designs and has moderate evidentiary confidence (Cocchiara et al., 1990; Narita et al., 2006).

The clinical translation is where confidence drops sharply. The puberty prevalence switch is well-documented (Pinart et al., 2017). But systematic, validated symptom tracking across confirmed menstrual cycle phases in women with allergic rhinitis — controlling for actual allergen exposure — does not exist. There are no adequately powered prospective studies. There are no direct comparisons between cycle-driven symptom variation and treatment effect sizes. There are no longitudinal data tracking daily oestradiol against daily symptom scores.

This matters because without knowing the magnitude of the effect, it's difficult to know how much weight to give it in your personal strategy. Is the ovulatory amplification the equivalent of a medium-pollen day's extra exposure? A high-pollen day's? Less than either? We genuinely don't know yet.

The contraceptive and menopause data are similarly limited by cross-sectional designs, absent mechanistic confirmation in nasal tissue specifically, and a near-complete lack of longitudinal follow-up. The pregnancy data are the most clinically actionable — the overlap between pregnancy rhinitis and allergic rhinitis is well characterised enough to guide treatment decisions — but even here, validated symptom instruments have rarely been applied systematically.

---

What Haelo recommends

Track your cycle alongside your symptoms. Even before science has the definitive answer, your personal data may show a pattern. Log your symptom severity daily and note where you are in your cycle. After two to three months, you'll have more signal than any current published study provides for your individual biology.

Expect a potential peak around ovulation. Based on available mechanistic and observational data, mid-cycle (days 12–16 of a 28-day cycle) is the most biologically plausible window for elevated nasal reactivity. On high-pollen days that coincide with this window, consider pre-medicating in the morning rather than waiting for symptoms to arrive.

Time your antihistamine in the evening. This applies regardless of cycle phase. Antihistamines taken at night reach peak plasma concentration by morning — when both pollen counts and your body's own histamine release tend to be highest.

If you're on hormonal contraception, don't assume your symptoms are 'balanced'. Your cycle-to-cycle variation may be flatter, but your baseline allergic load may be higher. Apply the same evidence-based management — daily intranasal corticosteroid, morning antihistamine — rather than assuming the pill is protective.

If you're pregnant, treat both conditions. Pregnancy rhinitis and allergic rhinitis are distinct problems that can co-exist and amplify each other. Discuss safe options with your GP or allergist — intranasal corticosteroids are generally considered low-risk in pregnancy, and untreated allergic rhinitis has its own risks for sleep quality and quality of life.

Around perimenopause, watch for shifting patterns. If your hayfever seems to behave differently — worse in some seasons, new sensitivities — this may not be coincidence. Erratic oestrogen fluctuation is a biologically plausible amplifier. Document the shift and bring it to a conversation with your GP.

Don't wait for the definitive study. The research that would fully answer these questions — a large, prospective, hormone-assayed, pollen-controlled symptom diary study — hasn't been done yet. In its absence, your own tracking data is the most personalised evidence available.

---

The associations described here are based on observational and mechanistic studies. Individual responses to hormonal fluctuation vary significantly. This article is not a substitute for personalised medical advice.